{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-330568","form_type":"8-K","ticker":"ORIC","cik":"0001796280","company_name":"Oric Pharmaceuticals, Inc.","filed_at":"2026-08-03T20:10:16+00:00","discovered_at":"2026-08-03T20:11:00.324982+00:00","generated_at":"2026-08-03T20:11:19.056165+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ORIC initiates Himalayas-1 Phase 3 trial for rinzimetostat; Q2 cash $387.6M, R&D $36.3M","bullets":["Initiated Himalayas-1 global Phase 3 registrational trial for rinzimetostat in mCRPC; ~600 patients, 25 countries, primary endpoint rPFS.","Entered clinical trial collaboration with Bayer to supply darolutamide at no cost for Himalayas-1; ORIC retains full rights to rinzimetostat.","Cash and investments $387.6M as of June 30, 2026; includes $59.9M net proceeds from ATM; runway into 2H 2028.","R&D expenses $36.3M for Q2 2026, up from $30.5M YoY; G&A $9.0M, up from $8.5M.","Anticipated milestones: rinzimetostat program update 2H 2026; enozertinib data at ESMO October 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-330568","json":"https://secwatch.observer/filing/0001193125-26-330568.json","markdown":"https://secwatch.observer/filing/0001193125-26-330568.md","text":"https://secwatch.observer/filing/0001193125-26-330568.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1796280/000119312526330568/0001193125-26-330568-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1796280/000119312526330568/oric-20260803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-03T20:11:19.056165+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}